Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News  >  Companies  >  All News

News : Companies

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors

Exiqon A/S - Exiqon A/S completes litigation against Santaris Pharma a/s

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/07/2011 | 08:20pm CET
Exiqon A/S
Company Announcement
Exiqon A/S completes litigation against Santaris Pharma a/s

Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced that the company has completed its litigation against Santaris Pharma a/s.

In 2010, Exiqon initiated arbitration proceedings to defend its business against Santaris Pharma.

Exiqon’s product offering includes LNA™ amidites and LNA™ oligonucleotides for the research and development of pharmaceutical products. Exiqon has the exclusive right to supply such products except for use in the research and development of pharmaceutical products containing LNA™ as the active ingredient. Today’s decision by the arbitration court establishes Exiqon’s non-exclusive right to supply these products also for the research and development of pharmaceutical products containing LNA™ as the active ingredient. Santaris Pharma’s request that Exiqon should be prevented from supplying LNA™ products for such use was dismissed.

Following today’s decision, it is clear that both Exiqon and Santaris Pharma may supply LNA™ products for the research and development of pharmaceutical products containing LNA™ as the active ingredient.

In a comment, President and CEO of Exiqon, Lars Kongsbak said: “Exiqon is committed to provide best in class products for the detection of nucleic acids using our LNA™ technology. This has allowed us to become a leader in our markets, and serves as the foundation for Exiqon’s commitment to develop, and help propel the development of, novel molecular diagnostic products, including companion diagnostics, for which we provide easy access to our proprietary technologies through licensing. Proceedings against Santaris Pharma were an unfortunate, but necessary, step towards realizing our business goals.”

Exiqon had requested that Santaris Pharma be ordered to pay damages. However, the arbitration court did not find grounds for damages.

During proceedings, Santaris Pharma submitted a counter claim against Exiqon for damages in the amount of DKK 100 million. This claim was dismissed on substantive grounds.

The arbitration court also decided on the distribution of the costs of proceedings. Santaris Pharma was awarded partial costs of DKK 2 million payable by Exiqon within 14 days.

Exiqon expect today’s decision to impact its full year EBITDA, for which guidance has been provided exclusive of one-time items, with approximately DKK -10 million.

Additional information
Lars Kongsbak, CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Hans Henrik Chrois Christensen, CFO, tel. +45 4566 0888 (cell: +45 4090 2131)

See the full press release in the attached PDF or at www.exiqon.com/investor/portal.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news "Companies"
10:42pROBBINS ARROYO LLP : Quantum Corporation (QTM) Misled Shareholders According to a Recently Filed Class Action
BU
10:41pHARLEY DAVIDSON : Mama Tried Takes Over Milwaukee
PU
10:40p2 DAY SEMINAR : Roadmap of California Medical Leaves (Los Angeles, United States - May 24-25, 2018) - ResearchAndMarkets.com
BU
10:40pGRUPO SUPERVIELLE S.A. : Reports 4Q17 Consolidated Results
BU
10:39pOLIN : to Attend the J.P. Morgan, Bank of America Merrill Lynch and Longbow Research Conferences
PR
10:36pVODAFONE : fleet management solution enhances Huawei’s Qatar transport operations
AQ
10:35pGrenada Telecoms Market Report 2018 - Subscriber & Penetration Rate Forecasts to 2025 for Mobile, Fixed Landline and Broadband - ResearchAndMarkets.com
BU
10:32pCORELOGIC : Los Alamitos homebuying dips 5% as sellers don't budge on prices
AQ
10:31pFMC CORPORATION : 's Mark Douglas and Paul Graves to Speak at The Bank of America Merrill Lynch 2018 Global Agricultural & Materials Conference
PR
10:31pNitinat Appoints John A. Gould as its Qualified Person for its Carscallen Gold Property
GL
Latest news "Companies"
Advertisement